EntryPoint Capital LLC Invests $92,000 in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

EntryPoint Capital LLC bought a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,784 shares of the specialty pharmaceutical company’s stock, valued at approximately $92,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 28.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock worth $43,000 after acquiring an additional 768 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $49,000. AJOVista LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $60,000. Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals during the first quarter worth approximately $121,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $126,000.

KalVista Pharmaceuticals Price Performance

Shares of KALV stock traded up $0.38 during midday trading on Friday, hitting $14.77. The company had a trading volume of 47,229 shares, compared to its average volume of 554,429. The company’s 50 day simple moving average is $12.34 and its 200 day simple moving average is $12.62. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.21 and a 52-week high of $16.88. The stock has a market cap of $631.27 million, a price-to-earnings ratio of -4.37 and a beta of 0.91.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.29). Analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.38 EPS for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Edward P. Feener sold 8,088 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $95,114.88. Following the completion of the sale, the insider now owns 72,858 shares in the company, valued at $856,810.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,512 shares of company stock worth $439,424. 12.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

KALV has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, July 15th. Needham & Company LLC cut their price target on KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, July 12th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.